Clinical Spotlight Series: Hypertriglyceridemia & CV Health-4. Emerging Treatment Options: The Latest Clinical Evidence

4. Emerging Treatment Options: The Latest Clinical Evidence

Video Transcription

Video Summary

The speaker reviews emerging treatments for severe hypertriglyceridemia (HTG) and familial chylomicronemia syndrome (FCS), highlighting recent guidelines and trials. For TG 500–999 mg/dL, clinicians should address secondary causes, optimize lifestyle and glycemic control, and use statins based on ASCVD/diabetes risk before adding fibrates or omega-3s. For TG ≥1,000 mg/dL, prompt fibrates/omega-3s are recommended to reduce pancreatitis risk. The talk focuses on ApoC-3 inhibitors: older volanesorsen lowered TGs markedly but caused thrombocytopenia. Newer agents (olezarsen, plozasiran) show major TG reductions and >80% pancreatitis risk reductions in FCS, leading to U.S. approvals and Class I guideline recommendations. CORE trials in severe HTG showed ~65% TG lowering and ~85% pancreatitis reduction.

Meta Tag

Concept Severe Hypertriglyceridemia

Concept Apolipoprotein C-III

Concept Familial Chylomicronemia Syndrome

Concept Secondary Causes

Concept Triglyceride Level

Keywords

hypertriglyceridemia

familial chylomicronemia syndrome

ApoC-3 inhibitors

pancreatitis risk reduction

triglyceride lowering

Severe Hypertriglyceridemia

Apolipoprotein C-III

Familial Chylomicronemia Syndrome

Secondary Causes

Triglyceride Level